Conducting DCTs while Maintaining Patient Safety & Engagement

8:50 am Chair’s Opening Remarks

9:00 am Establishing & Conducting an Oncology DCT


  • Understanding the importance of providing a DCT for oncology
  • Using DCT approaches to improve trial outcomes and data quality
  • Considering the additional requirements when conducting an expanded access
    program for gene therapies

10:00 am Reserved for Sponsor

10:30 am

Morning Break

11:00 am Creating & Executing Resilient Clinical Trials by Incorporating DCTs

  • Savo Topic Associate Director Digital Strategy, R&D, Takeda


  • Designing and implementing flexible protocols for DCTs
  • Leveraging best practices for minimizing the strain on patients
  • Finding and incorporating the most suitable technologies to streamline a DCT

11:30 am Utilizing Digital Capabilities while Conducting a DCT

  • Rakesh Maniar Head of eClinical Technologies, Global Data Management & Standards, Clinical Trial Operations, Merck


  • Outlining into the spectrum of clinical trials
  • Understanding which elements of a trial are most appropriate of site-based visits
  • Creating a bespoke trial for every clinical research opportunity

Looking Forward: The Future of Decentralized Clinical Trials

12:00 pm Interactive Group Discussion – Increasing the Scale of DCT to Match Adoption Rate


This interactive session will give you the opportunity to dive into the conversation with your fellow colleagues to discuss, debate and get inspiration on how to approach:

  • Determining where increased demand will originate from
  • Reviewing the different tools and methods to support the scaling up of DCTs
  • Ensuring data integrity is maintained during expansion

12:30 pm

Lunch Break

1:30 pm Increasing DCT Patient Retention Rates

  • James Hacunda Data Sciences Institute, Research & Development Digital Strategy Lead, Takeda


  • Effectively engaging with patients to support their needs in DCTs
  • Maintaining relationships and open communication with DCT patients
  • Avoiding patient fatigue during long term follow up periods in DCTs



You can’t run a DCT without technology – and with the technology that enables
these trials innovating at lightning speed, its vital that you know what best-in class
looks like! In this rapid-fire tech spotlight, three of the most innovative new DCTenabling
tech providers will give you a lightning-speed overview of how they can
revolutionize your DCT.

2:30 pm

Afternoon Break

3:00 pm Interactive Roundtable Discussion Groups


This interactive session will give you the opportunity to dive into the conversation with your
fellow colleagues to discuss, debate and get inspiration on how to approach specific challenges.
Choose the table most relevant to you and get ready to be part of this conversation!

3:45 pm Panel Discussion: Incorporating Underrepresented Diseases into DCTs

  • Hassan Kadhim Senior Director, Head of Clinical Trial Business Capabilities, Bristol Myers Squibb
  • Daniel Karlin Chief Medical Officer, MindMed


  • Outlining which conditions aren’t being supported by DCTs
  • Redesigning DCTs to include all disease areas
  • Engaging with different communities to support DCTs

4:30 pm The Future of DCTs – Lessons Learned & Thinking Beyond Covid

  • Lewis Millen Global Clinical Sciences & Operations Lead, UCB


  • Discussing the evolution of DCTs over the last two years
  • Looking forward to the opportunities with new technologies
  • Maintaining the momentum behind DCTs

5:00 pm Chair’s Closing Remarks & End of Conference